Skip to content

Omeros OMER Free cash flow margin

Discontinued — last reported Q3 '21

Free cash flow margin at other companies

Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-366.6%+1,421pp
Immunome logo
ImmunomeIMNM
-5,118.9%-8,601pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-207.2%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-3,561.6%-6,956pp
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
1.9%+1.0pp
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-474%+92.4pp

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$775.86M+313%
P/S8.6×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Calculated from Omeros’s reported figures.

Based on trailing twelve months.

The official record: Omeros’s 10-Q, filed November 9, 2021, on SEC EDGAR. View the filing →

Ask your AI about Omeros's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's free cash flow margin?
Omeros (OMER) reported free cash flow margin of -121.6% in Q3 2021.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.